| Product Code: ETC7664399 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market - Industry Life Cycle |
3.4 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market - Porter's Five Forces |
3.5 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.7 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.8 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness and acceptance of vasomotor menopausal symptoms (VMS) treatment in Israel |
4.2.2 Growing aging population in Israel leading to a larger target demographic for VMS treatment |
4.2.3 Advancements in medical technology and treatment options for VMS in Israel |
4.3 Market Restraints |
4.3.1 High cost associated with VMS treatment in Israel |
4.3.2 Lack of reimbursement coverage for VMS treatment by health insurance providers in Israel |
4.3.3 Cultural or societal stigmas surrounding menopause and VMS in Israel |
5 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends |
6 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Types |
6.1 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Antidepressants, 2021- 2031F |
6.1.4 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Fluoxetine, 2021- 2031F |
6.1.5 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Paroxetine, 2021- 2031F |
6.1.6 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Sertraline, 2021- 2031F |
6.1.7 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Hormone Therapy, 2021- 2031F |
6.1.8 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Anticonvulsant, 2021- 2031F |
6.1.9 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Phenobarbital, 2021- 2031F |
6.1.10 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Phenobarbital, 2021- 2031F |
6.2 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Route of Administration |
6.2.1 Overview and Analysis |
6.2.2 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Oral, 2021- 2031F |
6.2.3 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.2.4 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market, By End-Users |
6.3.1 Overview and Analysis |
6.3.2 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.3.4 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Homecare, 2021- 2031F |
6.3.5 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Distribution Channel |
6.4.1 Overview and Analysis |
6.4.2 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.4.3 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.4.4 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.4.5 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Others, 2021- 2031F |
7 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Import-Export Trade Statistics |
7.1 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Export to Major Countries |
7.2 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Imports from Major Countries |
8 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Key Performance Indicators |
8.1 Number of healthcare providers offering VMS treatment options in Israel |
8.2 Patient satisfaction rates with VMS treatment services in Israel |
8.3 Adoption rate of new VMS treatment technologies or therapies in Israel |
8.4 Number of clinical trials or research studies conducted on VMS treatment in Israel |
8.5 Rate of referrals to specialists for VMS treatment in Israel |
9 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market - Opportunity Assessment |
9.1 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.3 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.4 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market - Competitive Landscape |
10.1 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenue Share, By Companies, 2024 |
10.2 Israel Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here